MORRISVILLE, North Carolina, October 13, 2016 /PRNewswire/ --
Worldwide Clinical Trials (http://www.worldwide.com) will present a webinar, titled "Accelerating Analgesics Therapeutic Development by Optimizing Early Human Experimental Models of Pain," on Thursday, Oct. 27, 2016 at 11 a.m. E.T.
Leading the discussion during this free webinar will be Worldwide's Senior Medical Director of Neuroscience, Miroslav Backonja, M.D., who has played an integral role in the development of several experimental pain models. Board-certified in both neurology and pain medicine, Dr. Backonja has more than 100 peer-reviewed publications; serves on the editorial boards for a number of pain journals, including Pain, Pain Medicine, and Clinical Journal of Pain; and is a member of the American Academy of Neurology, the International Association for the Study of Pain, and the American Academy of Pain Medicine.
"The challenge that confronts investigators within analgesics therapeutic development is to match specific pain treatments based on different underlying pain mechanisms and to offer a treatment tailored to each patient," explained Dr. Backonja. "Experimental pain models offer a unique and unprecedented opportunity to facilitate the transition from preclinical to clinical phases of analgesic development, as these models are essential in both understanding underlying pain mechanisms and in assessing the efficacy of analgesic compounds very early in development."
Joining Dr. Backonja for the webinar discussion will be George Atiee, M.D., Vice President and Medical Director for Worldwide's Early Phase Services unit. Drs. Backonja and Atiee will discuss the ability of human experimental models of pain to translate and demonstrate the efficacy of new chemical entities in providing pain relief in humans in early phase studies, as well as their potential to inform later phases about dose range for registration trials. They will also highlight several human experimental pain models such as capsaicin, cold pressor test and UVB-burn; application techniques and associated outcome measures; and the potential of these models to significantly accelerate analgesic drug and interventions development.
To register for this free Worldwide Clinical Trials webinar, visit: http://go.worldwide.com/Accelerating_Analgesics_Dev_Webinar_Registration.html?sourceID=PR.
Connect with Worldwide Clinical Trials:
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit http://www.worldwide.com.
SOURCE Worldwide Clinical Trials
Advertisement
Worldwide Clinical Trials (http://www.worldwide.com) will present a webinar, titled "Accelerating Analgesics Therapeutic Development by Optimizing Early Human Experimental Models of Pain," on Thursday, Oct. 27, 2016 at 11 a.m. E.T.
Advertisement
Leading the discussion during this free webinar will be Worldwide's Senior Medical Director of Neuroscience, Miroslav Backonja, M.D., who has played an integral role in the development of several experimental pain models. Board-certified in both neurology and pain medicine, Dr. Backonja has more than 100 peer-reviewed publications; serves on the editorial boards for a number of pain journals, including Pain, Pain Medicine, and Clinical Journal of Pain; and is a member of the American Academy of Neurology, the International Association for the Study of Pain, and the American Academy of Pain Medicine.
"The challenge that confronts investigators within analgesics therapeutic development is to match specific pain treatments based on different underlying pain mechanisms and to offer a treatment tailored to each patient," explained Dr. Backonja. "Experimental pain models offer a unique and unprecedented opportunity to facilitate the transition from preclinical to clinical phases of analgesic development, as these models are essential in both understanding underlying pain mechanisms and in assessing the efficacy of analgesic compounds very early in development."
Joining Dr. Backonja for the webinar discussion will be George Atiee, M.D., Vice President and Medical Director for Worldwide's Early Phase Services unit. Drs. Backonja and Atiee will discuss the ability of human experimental models of pain to translate and demonstrate the efficacy of new chemical entities in providing pain relief in humans in early phase studies, as well as their potential to inform later phases about dose range for registration trials. They will also highlight several human experimental pain models such as capsaicin, cold pressor test and UVB-burn; application techniques and associated outcome measures; and the potential of these models to significantly accelerate analgesic drug and interventions development.
To register for this free Worldwide Clinical Trials webinar, visit: http://go.worldwide.com/Accelerating_Analgesics_Dev_Webinar_Registration.html?sourceID=PR.
Connect with Worldwide Clinical Trials:
- Tweet: @worldwidetrials experts to discuss the optimization of early human experimental models of pain. Register at http://go.worldwide.com/Accelerating_Analgesics_Dev_Webinar_Registration.html?sourceID=PR
- Follow us on Twitter: @worldwidetrials
- Find us on LinkedIn: https://www.linkedin.com/company/worldwide-clinical-trials-inc-
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit http://www.worldwide.com.
SOURCE Worldwide Clinical Trials
